Dan Dees
Showing 1–3 of 3 transcripts.
- Goldman Sachs22 min
AppLovin's Adam Foroughi: The Power of a Startup Mindset
AppLovin CEO Adam Farooqi leads the $200 billion mobile technology firm, which leverages a lean 400-person core team and advanced neural networks to dominate performance marketing and generate over $4 billion in annual EBITA. Following a near-total valuation collapse after its 2021 IPO, the company executed a strategic $5 billion share buyback program that restored over $100 billion in market value and drove stock prices to approximately $600 per share. Farooqi sustains this growth by enforcing a culture of extreme operational efficiency, mandatory AI integration for internal workflows, and direct personal oversight of all key hiring decisions.
- Goldman Sachs32 min
OpenAI CFO Sarah Friar on the race to build artificial general intelligence
Goldman Sachs and OpenAI leaders outline a strategic pivot toward full-stack infrastructure, highlighted by a $500 billion "Stargate" investment plan designed to secure 10 gigawatts of compute power for advanced reasoning models and autonomous agents. This capital deployment addresses severe hardware bottlenecks while driving breakthroughs in O-series models that now achieve PhD-level scientific proficiency and global coding supremacy. With revenue tripling annually and immediate plans to scale AI into education and enterprise banking, OpenAI aims to reach artificial general intelligence capabilities while treating an initial public offering as a long-term objective rather than an immediate priority.
- Goldman Sachs29 min
The pace of innovation in biotech: Mirador’s Mark McKenna
Former Prometheus Biosciences CEO Mark McKenna discusses the transformation of the biotech landscape from a pharma-dominated field to one driven by agile, high-risk companies like his current venture, Mirador Therapeutics, which recently secured $400 million in rapid fundraising. Drawing on his experience leading the $11 billion Merck acquisition of Prometheus, McKenna emphasizes that success now relies on leveraging generative AI for precision medicine, operating with a "speed as currency" philosophy to parallelize trials, and maintaining strategic secrecy to protect intellectual property against global competitors. The dialogue further outlines critical industry challenges, including the need to reform drug pricing models dominated by PBMs and to de-risk supply chains from over-reliance on Chinese manufacturing.